As the global biotech ecosystem becomes increasingly interconnected, in-licensing has evolved into a core growth engine, with US–Asia deal-making and NewCo formation continuing to accelerate as companies pursue capital-efficient paths to innovation and pipeline expansion. This session brings together executives, investors, and dealmakers shaping the next wave of cross-border collaboration to explore how the right assets are identified, regional rights are structured, and incentives are aligned across scientific, regulatory, and commercial stakeholders. Panelists will examine valuation trends, due-diligence best practices, and evolving partnership and NewCo models that are reshaping how biotech’s scale globally.